Buy  granules 2 g sachets 28 pcs
  • Buy  granules 2 g sachets 28 pcs

Strontium ranelate

K.O.Romparm Company S.R.L.
994 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

In in vitro studies, strontium ranelate:

  • stimulates bone formation in bone culture, and also stimulates the replication of osteoblast precursors and collagen synthesis in bone culture;
  • reduces bone resorption by suppressing the differentiation of osteoclasts, as well as their resorptive activity. As a result of the action of the drug, the balance between the formation and destruction of bone tissue changes towards the processes of bone formation.
  • The activity of strontium ranelate has been studied experimentally using various preclinical models. In particular, in experiments on intact rats, the use of strontium ranelate led to an increase in the trabecular bone mass, the number of trabeculae and their thickness, as a result of which the mechanical properties of the bone improved.

In the bone tissue of humans and experimental animals to whom the drug was prescribed, strontium ranelate was mainly absorbed on the surface of hydroxyapatite crystals and only to a small extent replaced calcium in these crystals in the newly formed bone.

Strontium ranelate does not alter the characteristics of bone crystals. According to the biopsy of the iliac crest, carried out after treatment with strontium ranelate at a dose of 2 g per day for up to 60 months in clinical studies, no adverse effect on bone quality or mineralization was found.

The combined effects of strontium distribution in bone tissue and increased absorption of X-rays by strontium compared to calcium lead to an increase in bone mineral density (BMD), which is measured by two-photon X-ray absorptiometry.

The data obtained to date indicate that these factors account for approximately 50% of the increase in the BMD index after 3 years of treatment with strontium ranelate at a dose of 2 g / day. These data should be taken into account when interpreting changes in the BMD index during treatment with strontium ranelate.

In clinical studies that confirmed the ability of strontium ranelate to reduce the risk of fractures, the mean BMD value increased in the group of patients treated with strontium ranelate compared with the baseline value - for the lumbar vertebrae by about 4% per year, and for the femoral neck by 2% per year; after 3 years, the increase in BMD was 13-15% and 5-6%, respectively (according to various studies).

Starting from the third month of therapy and within 3 years of follow-up, there was an increase in the indicators of biochemical markers of bone formation (bone fraction of alkaline phosphatase (ALP) and C-terminal propeptide of type I procollagen) and a decrease in indicators of bone resorption markers (cross-linked C-terminal and N-terminal telopeptides in urine) versus placebo.

For strontium ranelate, the secondary effect in relation to the main pharmacological properties is a slight decrease in serum concentrations of calcium and parathyroid hormone, as well as an increase in the concentration of phosphorus in the blood and the activity of total alkaline phosphatase, which, however, is not accompanied by any clinical effects.

Risk factors for postmenopausal osteoporosis are decreased bone mass, decreased BMD, early menopause, a history of smoking and family history of osteoporosis.

One of the most clinically significant complications of osteoporosis is the development of fractures, and the risk of fractures increases with an increase in the number of risk factors.

No customer reviews for the moment.

Write your review

Write your review

Strontium ranelate

Dosage and Administration

Treatment with STROMETTA can only be prescribed by a physician experienced in the treatment of osteoporosis.
The recommended daily dose is 2 g (contents of one sachet) per day.
Due to the fact that food, medications and food supplements of calcium, milk and dairy products can reduce the absorption of strontium ranelate, it is necessary to take the drug between meals, preferably at bedtime, at least 2 hours after meals.
The drug STROMETTA should be taken in the form of a suspension, for which the contents of one sachet must be stirred in one glass in at least 30 ml of water (approximately 1/3 of an ordinary glass).
The suspension is recommended to be taken orally immediately after use.
Due to the chronic nature of the disease, the drug STROMETTA is supposed to be taken for a long time.
Patients with osteoporosis taking STROMETTA should additionally take medications and / or dietary supplements of calcium and vitamin D if the intake of these substances is insufficient.
  • Brand name: Striks
  • Active ingredient: Strontium ranelate
  • Manufacturer: K.O.Romparm Company S.R.L.
  • Country of Origin: Romania

Studies and clinical trials of Strontium ranelate (Click to expand)

  1. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial
  2. Effect of strontium ranelate on fracture healing in the osteoporotic rats
  3. Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: Matrix incorporation of strontium is accompanied by changes in mineralization and microstructure
  4. Synthesis, characterization of strontium-bile acid salts and their bioactivity vs. the anti-osteoporosis drug strontium ranelate
  5. Le ranélate de strontium
  6. Corrélation entre l'augmentation de la DMO et la réduction du risque fracturaire lors d'un traitement par ranélate de strontium
  7. Efficacité antifracturaire sur cinq ans du ranélate de strontium chez les femmes âgées de 80 ans et plus
  8. Efficacité à long terme du ranélate de strontium contre les fractures vertébrales et non vertébrales
  9. En améliorant la microarchitecture osseuse, le ranélate de strontium réduit l'apparition de nouvelles fractures vertébrales dans un modèle murin d'ostéoporose sévère avec fractures spontanées
  10. Le ranélate de strontium stimule la réplication des ostéoblastes et réduit leur capacité ostéoclastogénique en modulant l'expression de l'ostéoprotégérine et du RANK ligand
  11. Effet du ranélate de strontium sur la consolidation de fractures du tibia
  12. Le ranélate de strontium diminue le risque de fractures vertébrales quel que soit le niveau initial de remodelage osseux
  13. Bénéfices à long terme du ranélate de strontium sur la qualité de vie des patientes atteintes d'ostéoporose vertébrale (étude SOTI)
  14. La dissociation entre formation et résorption osseuses est mise en évidence par des modifications des marqueurs biochimiques chez des patientes traitées par ranélate de strontium
  15. Le ranélate de strontium réduit la résorption endocorticale chez la souris atteinte d'ostéoporose sévère
  16. Le ranélate de strontium et le calcium exercent des effets cumulatifs sur les ostéoclastes en activant différentes voies de signalisation intracellulaires en aval des récepteurs sensibles au calcium
  17. Le ranélate de strontium favorise la différenciation des ostéoblastes humains primaires en ostéocytes
  18. Ranélate de strontium : une nouvelle approche de l'ostéoporose post-ménopausique
  19. Increased strontium uptake in trabecular bone of ovariectomized calcium-deficient rats treated with strontium ranelate or strontium chloride
  20. Strontium distribution in bones and tissues of strontium ranelate-administrated rats
  21. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis
  22. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate
  23. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies
  24. Strontium ranelate: a novel mode of action optimizing bone formation and resorption

2 other products in the same category: